Suggested Readings

Diagnostic performance of plasma pTau 217, pTau 181, Aβ 1-42 and Aβ 1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease.

Arranz J, Zhu N, Rubio-Guerra S, et al. Res Sq. 2023. [preprint available December 13, 2023]

The Alzheimer's disease clinical spectrum: diagnosis and management.

Atri A. Med Clin North Am. 2019;103(2):263-293.

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease.

Barthélemy NR, Saef B, Li Y, et al. Nat Aging. 2023;3(4):391-401.

Neuropathological stageing of Alzheimer-related changes.

Braak H, Braak E. Acta Neuropathol. 1991;82(4):239-259.

Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline.

Bucci M, Chiotis K, Nordberg A, et al. Mol Psychiatry. 2021;26(10):5888-5898.

MRI or 18F-FDG PET for brain age gap estimation: links to cognition, pathology, and Alzheimer disease progression.

Doering E, Antonopoulos G, Hoenig M, et al. J Nucl Med. 2024;65(1):147-155.

Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: the role of CSF biomarkers during the evolution of diagnostic criteria.

Dulewicz M, Kulczyńska-Przybik A, Mroczko P, et al. Int J Mol Sci. 2022;23(15):8598.

The probabilistic model of Alzheimer disease: the amyloid hypothesis revised.

Frisoni GB, Altomare D, Thal DR, et al. Nat Rev Neurosci. 2022;23(1):53-66. 

A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers.

Jack CR Jr, Bennett DA, Blennow K, et al. Neurology. 2016;87(5):539-547.

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Jack CR, Jr., Bennett DA, Blennow K, et al. Alzheimers Dement. 2018;14(4):535-562.

Biomarker Changes during 20 Years Preceding Alzheimer’s Disease

Jia J, Ning Y, Chen M, et al. N Engl J Med. 2024;390(8):712-722.

Development of Alzheimer's disease biomarkers: from CSF- to blood-based biomarkers.

Mankhong S, Kim S, Lee S, et al. Biomedicines. 2022;10(4):850.

Plasma biomarkers of alzheimer's disease: a review of available assays, recent developments, and implications for clinical practice.

Pais MV, Forlenza OV, Diniz BS. J Alzheimers Dis Rep. 2023;7(1):355-380.

Cerebrospinal fluid immune dysregulation during healthy brain aging and cognitive impairment.

Piehl N, van Olst L, Ramakrishnan A, et al. Cell. 2022;185(26):5028-5039.e5013.

Donanemab in Early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.

Sims JR, Zimmer JA, Evans CD, et al. JAMA. 2023;330(6):512-527.

Lecanemab in early Alzheimer’s disease.

van Dyck CH, Swanson CJ, Aisen P, et al. N Engl J Med. 2023;388(1):9-21.

Related activities
0.75 CME/CE

Top 10 Questions on Biomarkers in Early Alzheimer’s Disease

Improving Diagnosis and Use of Targeted Therapies

Faculty: R. Scott Turner, PhD, MD, FANA, FAAN; James E. Galvin, MD, MPH
Release: 03/28/2024
Expiration: 03/28/2025